FDA warns motionpharmacy.com over selling unapproved and misbranded prescription drugs online.
What happened
FDA reviewed the website www.motionpharmacy.com and found it offering opioids, benzodiazepines, Schedule II stimulants, and semaglutide for sale to U.S. consumers. FDA says these are unapproved and misbranded drugs, and that the site offers prescription drugs without a prescription.
What FDA found
The website sells unapproved new drugs—products without FDA-approved applications—including opioids, benzodiazepines, stimulants, and semaglutide.
FD&C Act §§ 301(d), 505(a) [21 U.S.C. §§ 331(d), 355(a)]The drugs are misbranded because their labeling lacks adequate directions for a layperson to use them safely.
FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]The website offers prescription drugs for sale without a prescription.
FD&C Act § 503(b)(1) [21 U.S.C. § 353(b)(1)]FDA says the site causes misbranded drugs to be introduced into interstate commerce by offering them for sale to U.S. consumers.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA requests that motionpharmacy.com stop offering any unapproved and misbranded drugs for sale to U.S. consumers. The letter does not state a response deadline.
Who should pay attention
- online pharmacies and telehealth sellers of prescription drugs
- platforms hosting or linking to pharmacy websites
- clinicians and consumers who rely on legitimate prescription drugs
This is a summary. Read the original letter on fda.gov.